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Evidence for Altered Glutamine Metabolism
in Human Immunodeficiency Virus Type 1
Infected Primary Human CD4+ T Cells
Andrea Hegedus,1 Maia Kavanagh Williamson,1 Mariam B. Khan,1 Julianna Dias Zeidler,2
Andrea T. Da Poian,2 Tatiana El-Bacha,3 Eduard A. Struys,4 and Hendrik Huthoff1,*
Abstract
Glutamine is a conditionally essential amino acid that is an important metabolic resource for proliferating
tissues by acting as a proteinogenic amino acid, a nitrogen donor for biosynthetic reactions and as a substrate for
the citric acid or tricarboxylic acid cycle. The human immunodeficiency virus type 1 (HIV-1) productively
infects activated CD4+ T cells that are known to require glutamine for proliferation and for carrying out effector
functions. As a virus, HIV-1 is furthermore entirely dependent on host metabolism to support its replication. In
this study, we compared HIV-1 infected with uninfected activated primary human CD4+ T cells with regard to
glutamine metabolism. We report that glutamine concentrations are elevated in HIV-1-infected cells and that
glutamine is important to support HIV-1 replication, although the latter is closely linked to the glutamine
dependency of cell survival. Metabolic tracer experiments showed that entry of glutamine-derived carbon into
the citric acid cycle is unaffected by HIV-1 infection, but that there is an increase in the secretion of glutamine-
derived glutamic acid from HIV-1-infected cells. Western blotting of key enzymes that metabolize glutamine
revealed marked differences in the expression of glutaminase isoforms, KGA and CAG, as well as the PPAT
enzyme that targets glutamine-derived nitrogen toward nucleotide synthesis. Altogether, this demonstrates that
infection of CD4+ T cells with HIV-1 leads to considerable changes in the cellular glutamine metabolism.
Keywords: HIV-1, CD4+ T cells, glutamine, glutamic acid, metabolism, glutaminase
Introduction
L ike all viruses, human immunodeficiency virus type 1(HIV-1) is entirely dependent on host cells to provide the
metabolic resources to support its replication. While HIV-1 is
able to infect several types of immune cells, its productive and
lytic replication occurs predominantly in activated CD4+ T
cells, but restingCD4+Tcells are refractory toHIV replication.
The transition from resting to activated CD4+ T cells is known
to coincide with a metabolic switch that is characterized by the
upregulation of glycolysis and glutaminolysis in activated
cells.1,2 The field of immunometabolism has recently attracted
increasing interestwith regard to understanding howmetabolic
processes support immunological effector functions and the
potential therapeutic exploitation thereof.3,4
Likewise, understanding the metabolic requirements of
viral infections holds the promise of identifying new antiviral
strategies.5 Viral dependency on and modulation of cellular
metabolism has now been demonstrated for a diverse set of
viruses, including human cytomegalovirus (HCMV), herpes
simplex virus type 1 (HSV-1), Influenza, Sindbis, Mayaro,
Dengue, and HIV.5–17 Currently, the best-documented example
is HCMV, which has been shown to depend on fatty acid syn-
thesis to support membrane production for virion assembly.5–7
This work has provided proof of principle that fatty acid syn-
thesis can be targeted as an antiviral strategy against HCMV
infections.5,18 Comparison with the closely related HSV-1 virus
furthermore rationalized the differential efficacy of nucleotide
inhibitors as inhibitors of the two herpesviruses, with HCMV
being less dependent on nucleotide synthesis than HSV-1.12
1Department of Infectious Diseases, King’s College London, London, United Kingdom.
2Instituto de Bioquı´mica Me´dica Leopoldo de Meis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
3Instituto de Nutric¸a˜o Josue´ de Castro, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
4Metabolic Unit, Department of Clinical Chemistry, VU Medical Center, Amsterdam, the Netherlands.
*Current affiliation: Jena School for Microbial Communication, Friedrich Schiller University Jena, Jena, Germany.
ª Andrea Hegedus et al. 2017; Published by Mary Ann Liebert, Inc. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original
work is properly cited.
AIDS RESEARCH AND HUMAN RETROVIRUSES
Volume 33, Number 12, 2017
Mary Ann Liebert, Inc.
DOI: 10.1089/aid.2017.0165
1236
We have previously reported that HIV-1 replication is de-
pendent on the highly glycolytic phenotype of activated CD4+
T cells and infection of these cells with HIV-1 further elevates
their glucose consumption.11 This work corroborated an
earlier report that glycolytic intermediates are elevated in
HIV-1-infected versus -uninfectedCD4+Tcells.10 In addition
to glucose, glutamine is an important metabolic resource for
activated T cells and indeed more generally for proliferating
tissues.2 We, therefore, set out to determine if glutamine
metabolism is in any way affected by the infection of CD4+ T
cells with HIV-1. There is ample precedence for viral depen-
dency on or manipulation of glutamine metabolism by viruses
as diverse as hepatitus C virus (HCV),19 Adenovirus,20 in-
fectious spleen and kidney necrosis virus (ISKNV),21 Kaposi
sarcoma herpes virus (KSHV),22 Vaccinia virus,23HCMV-1,24
and Dengue virus.25
We report that glutamine metabolism of primary human
CD4+ T cells is responsive to HIV-1 infection as evidenced
by increased intracellular glutamine concentrations and in-
creased secretion of glutamine-derived glutamic acid. Inter-
estingly, entry of glutamine-derived carbon into the citric
acid cycle is unaffected by infection with HIV-1, but the
expression of several enzymes that metabolize glutamine into
glutamic acid is altered in HIV-1-infected cells.
Materials and Methods
Cell culture
Whole blood was obtained from healthy volunteers by
venipuncture and peripheral blood mononuclear cells were
isolated by density gradient centrifugation using Lympho-
prep according to the manufacturer’s instructions (Axis-
Shield). CD4+ T lymphocytes were isolated by magnetic
sorting using the CD4+ Isolation Kit II (Miltenyi Biotec).
Purity of isolated population was assessed by flow cytometry,
and was typically >95%. Human primary lymphocytes were
cultured in RPMI-1640 media supplemented with 10% fetal
bovine serum (FBS), 1% penicillin/streptomycin (P/S), and
15 IU/ml interleukin 2 (IL-2) following activation with CD3/
CD28 T cell activator Dynabeads (all from Invitrogen).
CD4+ T cell lines, Jurkat and CEM-ss, were maintained in
RPMI-1640 with 10% FBS and 1% P/S. Human endothelial
kidney293T (HEK293T)andTZM-bl cellsweremaintained in
high-glucoseDulbecco’smodified Eagle’smedium (DMEM;
Invitrogen) supplemented with 10% FBS and 1% P/S.
Media for glutamine titration and metabolic tracer experi-
ments were made up from DMEM powder (Sigma) lacking
glucose, pyruvate, glutamine, sodium bicarbonate, and phenol
red; these components were added to obtain standard DMEM
formulation with 1 g/liter glucose, 10mM pyruvate, 0, 0.2, 0.5
and 1mM final glutamine concentration. Media containing
13C-labeled glutamine (Gln-3-13C) and pyruvate (Pyr-2-13C)
for enrichment analysis bymass spectrometryweremade using
DMEM powder as above, with 2mM glutamine and pyruvate
(1mM labeled and 1mM unlabeled compound; all from Sig-
ma). Media with universally labeled U-13C-glutamine (Sigma)
for nuclearmagnetic resonance (NMR) analyseswere prepared
as above with 2mM final U-13C-glutamine concentration.
All these media were supplemented with 10% dialyzed
FBS (Sigma) and 1% P/S (Invitrogen), pH adjusted to 7.2–
7.4, and filter sterilized before use. All cell cultures were
maintained at 37C with 5% CO2.
Virus production and infection
NL4.3 wild-type (wt) and Env-deleted (DEnv negative con-
trol) viruses were produced by transfection of HEK 293T cells
with molecular clones using polyethylenimine (PEI) (Poly-
sciences) as described previously.11 Vesicular stomatitis virus
glycoprotein (VSV-G) pseudotyped NL4.3 virus was made by
cotransfection with NL4.3 molecular clone and VSV-G ex-
pression vector for infection of Jurkat cells. Supernatant from
transfected cells was purified by filtering through 0.45lmfilter
(Millipore), and NL4.3 and NL4.3-DEnv viruses were further
concentrated using ultracentrifugation over 20% sucrose cush-
ion for 75min at 28,000 rpm. Virus pellets were resuspended in
serum- and glucose-free DMEM and virus infectivity was de-
termined by titration on CEM-ss and Jurkat cells with subse-
quent intracellular p24Gag staining and flowcytometry analysis.
Cell samples for the intracellular amino acid level determi-
nation, 13C-tracing experiments, and western blotting were
included for analysis if a minimum 70% of the cells stained
positive for p24Gag cells by flow cytometry at 24 h postinfec-
tion. Uninfected control samples received an equal volume of
ultracentrifuge-purified noninfectiousDEnvNL4.3 virus stock.
For NMR experiments with U-13C-glutamine experiments,
samples were included if at least 50% of the cells stained pos-
itive for p24Gag at 24 h postinfection. Experiments addressing
virus replication and caspase 3 activation in glutamine-limiting
conditionswereperformedwith cell preparations,wherein 1%–
10% of the cells stained positive for p24Gag at 24 h after in-
fection, and thesewere subsequently split into cultures with the
indicated glutamine concentrations ranging from 0 to 1mM.
Mass spectrometry
Cells were washed in phosphate-buffered saline (PBS) three
times before pelleting at 1,200 rpm for 10min. Pellets were
then snap frozen over a mixture of 70% methylated spirit and
dry ice and stored at -80C. Once all samples were collected,
pellets were thawed, and metabolites were extracted with
200ll 80% liquid chromatography-grade methanol (Merck)/
demineralized water that was chilled at -20C. Samples were
mixed by vortexing and centrifuged for 10min at a maximum
speed on a benchtop Eppendorf centrifuge at 4C. The liquid
phase was collected and transferred to a clean Eppendorf tube,
the precipitate was kept to determine the protein content of
each sample using a BCA assay. Amino acid concentrations
were determined using a Biochrom 30 Amino Acid Analyzer
equipped with postcolumn ninhydrin derivatization.
Incorporation of 13C-labeling into glutamine, glutamic acid,
aspartic acid, and citric acid was assessed by liquid chroma-
tography coupled mass spectrometry (LC-MS/MS) according
to the procedure of Mills et al.26 Briefly, glutamine, aspartic
acid, and glutamic acid were converted into their fluor-
enylmethyloxycarbonyl (FMOC) derivatives and injected onto
the analytical C18 column. Incorporation of
13C-labeling into
citratewas assessed according to amodified procedure ofBlom
et al.27 The mass spectrometer (AB Sciex 4000 Q-trap) oper-
ated in the negative ionization mode, and the isotopomers of
glutamine, glutamic acid, aspartic acid, and citric acid were
measured by specific mass transitions.
Measurement of protein content
Cell pellets were resuspended in 500 ll lysis buffer con-
taining 5% Triton-X, 5% sodium dodecyl sulfate (SDS) and
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3% urea, heated at 95C for 10min, then vortexed and spun at
4C for 10min at 400 · g. Once cooled to room temperature,
samples were sonicated over ice for 30 s then rested on bench
for 1 h. Protein content was measured with the Pierce BCA
Protein Assay Kit (Thermo Fisher Scientific) according to the
manufacturer’s instructions.
Flow cytometry
Cells were washed in PBS and treated with TrypLE (both
Sigma) to remove surface-bound virus particles, then fixed
and permeabilized with Cytofix/Cytoperm (BDBiosciences).
Samples were then stained with anti-p24Gag-RD1 (KC57-
RD1) (Beckman Coulter) antibody only, or in combination
with anti-active caspase 3-FITC antibody (clone C92-605;
BD Biosciences) at concentrations and incubation times re-
commended by the manufacturers.
Surface expression of CD4 was determined by staining with
antibody 555347 from BD Biosciences according to the man-
ufacturer’s instructions.Cellswere thenwashed influorescence-
activated cell sorting (FACS) buffer (PBSwith 2%FBS and 1%
P/S), resuspended in 200ll FACS buffer and acquired on a
FACSCantoII machine (BD Biosciences). Absolute cell counts
were determined using CountBright beads (Life Technologies)
after fixing samples with 4% paraformaldehyde. Data were
analyzed with FlowJo software (TreeStar).
Western blotting
Cell and supernatant samples were separated by SDS–
polyacrylamide gel electrophoresis (SDS-PAGE) on 11% gel
for p24Gag and 15% gels, according to the size of the target
proteins, at 27mA per gel. Proteins were transferred onto nitro-
cellulose membrane overnight at 16V and blocked for 1h with
1% fat-free milk in 0.1% Tween/PBS. Membranes were incu-
batedwithprimaryantibodies at roomtemperature for at least 1 h.
The following primary antibodies were used: anti-HIV-1
Gag antibody (mouse hybridoma 183-H12-5C supernatant—
kind gift from Prof. M. Malim), anti-GFPT1 (Abcam
AB125069), anti-KGA (Proteintech 20170-1-AP), anti-GAC
(Proteintech 19958-1-AP), anti-PPAT (OriGene TA504769S)
and anti-HSP90 (Santa Cruz sc-7947). After incubation with
primary antibodies, membranes were washed and incubated
with secondary antibodies 680RD goat anti-mouse 926-68070
and 800CW goat anti-rabbit 926-32211 (both LI-COR) at
room temperature for 1 h. Membranes were then washed again
before visualization with a quantitative LI-COR imager.
Infectivity assay
TZM-bl indicator cells were plated at 1.5 · 105 per well in
a 24-well plate and incubated overnight to reach confluent
monolayer. Next day, 100 ll of supernatant from cultures was
added to each well and incubated for 24 h. Media were then
aspirated and cells were lysed using 100ll Galacto-Star
Lysis solution (Applied Biosciences). Cell lysates were kept
at -20C and thawed on the day of analysis. Once all samples
were collected, b-galactosidase activity was determined with
the Galacto-Star Reporter Assay Kit (Applied Biosciences)
according to the manufacturer’s instructions, and lumines-
cence was measured with Victor Luminometer (Perki-
nElmer). Values of negative control wells were deducted to
account for any autoluminescence present in TZM-bl cells.
p24 enzyme-linked immunosorbent assay
Samples were diluted 1:500 in 0.5% Triton, then p24
protein levels were measured using the Alliance HIV-1 p24
Antigen ELISA (enzyme-linked immunosorbent assay) Kit
according to the manufacturer’s instructions (PerkinElmer).
Plates were read on a Bio-Rad plate reader set to dual
wavelength at 405 and 630 nm.
NMR analysis
Metabolite efflux was evaluated byNMR.After infection of
cells with HIV-1 for 24 h, culture medium was replaced with
fresh DMEM from powder formulation (Sigma) supplemented
with 2mMU-13C-glutamine. At specific time intervals (1, 2, 3,
and 24 h), 0.5ml aliquots were collected from the culture me-
dium to evaluate 13C-metabolites efflux into the culture me-
dium. The same volume of medium was replaced to achieve a
constant U-13C-glutamine ‘‘pulse’’ during the experiment.
The 0.5ml of harvested supernatant was mixed with 1.1ml
100% prechilled methanol to precipitate proteins. Samples
were pipette mixed, vortexed, and spun at 14,000 rpm for
15min at 4C. Clear extracts were transferred into new tubes
and dried in a vacuum concentrator (Eppendorf). Samples
were resuspended in 600ll 50mM sodium phosphate buffer
containing 10% deuterated water (2H2O), pH 7.0. To evaluate
the kinetics metabolites efflux, one-dimensional 13C spectra
were obtained at 298K, using 45 pulses with a repetition
time of 0.6 s, 16,000 complex points, 2,028 scans, and a
spectral width of 200 p.p.m. The free-induction decays were
zero filled to 16,384 points and apodized with exponential
multiplication using line broadening of 10Hz. Spectra were
acquired with a Bruker Advance 500MHz instrument.
Spectral processing and analysis was performed using
Topspin 3.5. Glutamine and other metabolites were assigned
using theHumanMetabolomeDatabase v 3.628 and quantified
by their peak integrals. For glutamine, as well as glutamic
acid, carbons 3 and 4 have the highest intensity peaks in the
13C NMR spectra and these were therefore used for quantifi-
cation. The highest intensity peak for lactic acid was carbon 3.
Statistics
GraphPad Prism software was used to perform two-tailed
t-test to calculate p-values.
Results
HIV-1 replication and CD4+ T lymphocyte viability
are dependent on glutamine
To identify differences between uninfected and HIV-1-
infected primary human CD4+ T cells with regard to amino
acid metabolism, we analyzed cell lysates for amino acid
content on a Biochrom 30 Amino Acid Analyzer (Fig. 1).
Primary CD4+ T cells were activated with anti-CD3/CD28-
coated beads in the presence of IL-2 and infected with the
virus stocks of HIV-1 NL4.3 molecular clone at high multi-
plicity of infection for 48 h, such that at least 70% of the cells
were positive by intracellular staining for the HIV-1 p24Gag
protein by flow cytometry (not shown). Control cells were
treated with an equivalent inoculum of Env-deleted nonin-
fectious NL4.3 DEnv and accordingly showed no expression
of p24Gag. Samples were normalized to the protein content in
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each sample as determined with the BCA assay of the
methanol precipitate of the cells.
Analysis of amino acid abundance revealed that the in-
tracellular concentration of glutamine was significantly ele-
vated in the HIV-1 NL4.3-infected cells compared with the
uninfected controls. Although there was a tendency toward
elevated concentrations of other amino acids such as leucine,
serine, and lysine in the HIV-1-infected cells, none of these
reached statistical significance. In addition, a trend toward
reduced intracellular concentrations of glutamic acid was
observed, but this was also not statistically significant
(Fig. 1).
FIG. 1. Intracellular amino acid content of HIV-1-infected versus uninfected primary human CD4+ T cells. Scales on the
Y-axis indicate the intracellular concentration of each amino acid, as indicated at the top of individual plots, in micromolar
per milligram of protein in the corresponding cell sample. Uninfected cells were inoculated with an Env-deleted (DEnv)
preparation of HIV-1 NL4.3 corresponding to the same amount of p24Gag of wild-type NL4.3 that was added to the infected
samples (NL4.3). Glutamine emerged as the only proteinogenic amino acid that showed a statistically significant elevated
concentration in the infected cells with p= .0075. Phosphoethanolamine and taurine were significantly reduced in abundance
in the HIV-1-infected versus uninfected cells (DEnv). HIV-1, human immunodeficiency virus type 1.
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In addition to the proteinogenic amino acids, the amino acid
analysis also detected the presence of the sulfonic acid taurine
and the polyprotic acid phosphorylethanolamine. Both these
compounds were significantly reduced in abundance in the
lysate of HIV-1 NL4.3-infected cells compared with unin-
fected cells, demonstrating that normalization to protein con-
tent in the samples did not introduce a bias toward increased
amino acid abundance in the infected samples. Therefore,
HIV-1-infected primary human CD4+ T cells have a higher
intracellular glutamine concentration than uninfected cells and
lower concentrations of taurine and phosphorylethanolamine.
Because glutamine is one of the major metabolic resources
that CD4+ T cells require for survival, proliferation, and ef-
fector function,1,2 we sought to investigate the dependency of
HIV-1 replication on this amino acid. Spreading HIV-1 NL4.3
infectionsweremonitored in cultures of activated humanCD4+
T lymphocytes in the presence of titrated amounts of supple-
mented glutamine at 1.0, 0.5, 0.2, and 0mM. To ensure that the
infection was identical for each condition, we inoculated a
culture containing 1.0mM glutamine with HIV-1 NL4.3 for
24 h, after which the cells were washed with PBS to remove
glutamine repletemedia and the cellswere then split intomedia
with the titrated glutamine concentrations.
We note that we used dialyzed serum to minimize the
amount of glutamine introduced into the culture by the ad-
dition of FBS, but it is likely that the cultures with no added
glutamine would still contain trace amounts of this amino
acid from the FBS.
We assessed several parameters in these cultures: the
amount of HIV-1 p24Gag released into the culture by ELISA,
infectious virus in the culture supernatant using the TZM-bl
indicator cell line, and the proportion of cells expressing
p24Gag, as well as the apoptotic marker activated caspase 3 by
flow cytometry. The infectivity of the culture supernatant
(Fig. 2A) as well as the amount of released p24Gag (Fig. 2B)
consistently decreased with lower glutamine concentrations,
as is shown for a representative experiment in Figure 1.
In the absence of any added glutamine, neither p24Gag in the
culture nor the production of infectious virionswas detected. In
correlation with the reduced viral output at limiting glutamine
concentrations anduponglutamine starvation, the proportion of
cells in the culture that expressed the p24Gag protein was re-
duced to*70% at 0.2mM glutamine and 30% at 0mM glu-
tamine of the values obtained at 1mM glutamine after 24 h of
the provision of the limiting glutamine concentrations (Fig. 2C,
D). This suggests that HIV-1-infected CD4+ T cells are more
dependent on glutamine for survival than uninfected cells.
Theflowcytometry analysis of intracellular activated caspase
3 furthermore demonstrated that glutamine is required for T cell
viability as caspase 3 activation remained stable in cultures
containing 1.0, 0.5, and 0.2mM added glutamine, but it was
elevated in the glutamine-starved culture. This was observed in
both infected anduninfected cultures (Fig. 2D).While these data
indicate that HIV-1 replication is dependent on glutamine, we
were unable to unequivocally dissect the effect of glutamine
starvation on virus replication from effects on cell physiology.
Tracking the fate of glutamine in HIV-1-infected
and uninfected cells with 13C-stable isotope labeling
Apart from acting as a proteinogenic amino acid, gluta-
mine also has an important role in anaplerotically driving the
citric acid cycle in cells that do not use glycolysis-derived
pyruvate to support oxidative phosphorylation. Indeed, T
cells are known to significantly utilize glutamine in this
manner.2 To assess the origin of carbon in the citric acid cycle
in HIV-1-infected and uninfected cells, we supplemented
HIV-1 NL4.3wt andDEnv inoculated cultures after 24 h with
a 1:1 ratio of 12C/13C glutamine (Gln-3-13C) or pyruvate
(Pyr-2-13C) and incubated for a further 24 h.
We confirmed that the cells had been infected to a highMOI,
with a minimum of 70% of the cells containing intracellular
HIV-1 p24Gag (not shown). We included cultures of the T cell
lines Jurkat and CEM-ss that were infected and supplemented
with 12C/13C glutamine or pyruvate in the samemanner. Jurkat
cells were infected with a VSV-G-pseudotyped HIV-1 NL4.3
preparation to achieve the high percentage of infected cells.
Upon extraction of the intracellular metabolites, we analyzed
the percentage of 12C and 13C present in glutamine, glutamic
acid, aspartic acid, and citric acid by LC-MS.
Glutamic acid is an important intermediate for entry of
glutamine into the citric acid cycle as a-ketoglutarate, which
is driven by sequential action of the glutaminase and gluta-
mate dehydrogenase or glutamate transaminase enzymes.
Aspartic acid can be derived from and converted to oxalo-
acetate by glutamate oxaloacetate transaminase and serves as
an indirect read out of the carbon content of the citric acid
cycle. Citric acid, likewise, provides an indirect measure of
the relative amounts of 12C and 13C present in the citric acid
cycle derived from glutamine or pyruvate, as it can also be
generated from acetyl-CoA through fatty acid oxidation.
The analysis of 13C enrichment in glutamine confirmed that
the intracellular concentrations reflected the 1:1 ratio (or 50%
13C) of 12C- to 13C-containing glutamine thatwe supplemented
the cultures with (Fig. 3A). In addition, we observed only very
low amounts of 13C-labeled glutamine, glutamic acid, aspartic
acid, and citric acid in cultures that had been provided with the
1:1 mixture of 12C/13C-containing pyruvate, confirming that
very little pyruvate enters the citric acid cycle in T cells. This
was unaffected by infection of either primary CD4+ T cells or
the T cell lines, CEM-ss and Jurkat, with HIV-1 NL4.3.
We also observed that the glutamic acid contained*45%
of 13C (Fig. 3B), demonstrating that the majority of the in-
tracellular glutamic acid is derived from glutamine (*90%).
Aspartic acid and citric acid contained an average of 35% of
13C (Fig. 3C, D, respectively), again demonstrating that the
majority of carbon in the citric acid cycle is derived from
glutamine in T cells.
A clear difference in 13C enrichment in glutamic acid was
observed between the primary CD4+ T cells and the cell lines
after infection with HIV-1. While the 45% 13C content was
unaffected in HIV-1 NL4-3-infected primary CD4+ T cells, it
was reduced to*35% in CEM-ss and Jurkat cells (Fig. 3B).
A similar reduction was observed with the cell lines upon the
analysis of 13C enrichment in aspartic and citric acid, indi-
cating that the utilization of glutamine as a substrate for the
citric acid cycle is reduced upon infection of the T cell lines,
CEM-ss and Jurkat (Fig. 3C, D). The 13C enrichment of as-
partic acid and citric acid was unaffected by the infection of
primary CD4+ T cells with HIV-1.
These observations are in line with our previous studies, in
which we monitored the lactic acid production and oxygen
consumption of infected primary CD4+ T cells as well as
CEM-ss and Jurkat cells.11 Those analyses indicated that
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oxygen consumption of primary cells is unaffected by in-
fection with HIV-1 and that CEM-ss and Jurkat cells show
very different metabolic responses to HIV-1 infection than
primary CD4+ T cells do in that their oxidative metabolism is
reduced on infection with HIV-1. Importantly, these analyses
demonstrate that in primary human CD4+ T cells, glutamine
is the principal source of intracellular glutamic acid and the
primary substrate of the citric acid cycle. This is unaffected
by infection of the primary CD4+ T cells with HIV-1 NL4.3.
Having investigated the intracellular fate of glutamine in
infected primary T cells, we next sought to interrogate the
glutamine-derived exometabolome (the secreted metabo-
lites) of uninfected and infected primary CD4+ T cells. For
this purpose, we again established highly infected cultures
and supplemented these, as well as the uninfected controls,
with uniformly 13C-labeled glutamine after 24 h of infection.
Aliquots of the supernatant from these cultures were har-
vested over a time course of an additional 1, 2, 3, and 24 h
after the supplementation with 13C-glutamine and these
samples were subjected to 13C NMR analysis (Fig. 4A, B).
The C3 and C4 carbon peaks for glutamine were readily
identifiable and confirmed as the highest intensity peaks for
FIG. 2. The effect of limiting glutamine concentrations on HIV-1 replication and caspase 3 activation. (A) An HIV-1
spreading infection in a culture of activated human CD4+ T cells at limiting glutamine concentrations as monitored by
infectivity of the culture supernatant using the TZM-bl indicator cell line. The scale on the Y-axis in RLU indicates relative
luciferase units that are an indirect measure for HIV-1 infectivity as the TZM-bl cells contain the luciferase gene under the
control of the HIV-1 LTR promoter. (B) The HIV-1 p24Gag concentration (pg/ml) in the cultures shown in (A) as
determined by ELISA. (C) The amounts of p24Gag-expressing cells in cultures with limiting glutamine (Gln) concentra-
tions relative to p24Gag-expressing cells at 1.0mM glutamine. (D) Representative determination of the intracellular
abundance of activated caspase 3 (Y-axis) and HIV-1 p24Gag in HIV-1 infected (NL4.3) and uninfected (DEnv) cultures of
activated primary human CD4+ T cells at limiting concentrations of glutamine by flow cytometry. Numbers in the corners of
each quadrant indicate the percentage of cells that stained singly positive for caspase 3 or p24Gag, cells that were double
positive or negative. Statistical significance is indicated by asterisks with ****p £ .0001. ELISA, enzyme-linked immu-
nosorbent assay.
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the carbons in glutamine with control spectra. As the time
course progressed, peaks for carbons 3 and 4 of glutamic acid
and carbon 3 for lactic acid started to appear in the spectra
that were also identified by the use of reference spectra. In-
terestingly, the signal for glutamic acid was more prominent
and occurred at earlier time points in the infected compared
with the uninfected cultures (Fig. 4A). By 24 h after sup-
plementation with 13C glutamine, it was evident that the
concentration of 13C glutamic acid was significantly higher in
the infected cultures (Fig. 4B).
Conversely, the concentration of 13C lactate was reduced
in infected compared with uninfected cultures (Fig. 4B).
These results indicate increased secretion of glutamine-
derived glutamic acid and decreased secretion of glutamine-
derived lactic acid from infected versus uninfected primary
CD4+ T cells. Because we detected no signal for other 13C-
labeled compounds, this rules out the possibility that
infection-induced cell lysis is responsible for the observed
changes in glutamic and lactic acid concentrations in the
culture supernatants. We, therefore, conclude that infection
of primary CD4+ T cells with HIV-1 results in an increased
secretion of glutamine-derived glutamic acid and decreased
secretion of glutamine-derived lactic acid.
Differential expression of glutamine-metabolizing
enzymes upon infection with HIV-1
Since we observed differential secretion of glutamine-
derived metabolites from HIV-1-infected and uninfected
cells, we sought to establish whether this coincided with
differential expression of enzymes that act on glutamine.
Owing to the important and diverse roles that glutamine plays
FIG. 3. Metabolic tracing of the fate of intracellular glutamine in HIV-1-infected and uninfected T cells by 13C en-
richment mass spectrometry analysis. Cells cultured in media containing a 1:1 ratio of 12C to 13C mono-labeled glutamine or
pyruvate, as indicated on the X-axis. The percentage of 13C was determined by mass spectrometry for cell-extracted
glutamine (A), glutamic acid (B), aspartic acid (C), and citric acid (D). The experiments were performed with six different
donors for activated primary human CD4+ T cells as well as three independent replicates of the cell lines CEM-ss and
Jurkat. Jurkat cells were infected with VSV-G-pseudotyped HIV-1. Statistical significance is indicated by asterisks with
*p £ .05, **p £ .01, and ***p £ .001. VSV-G, vesicular stomatitis virus glycoprotein.
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in metabolism and protein synthesis, there are a considerable
number of enzymes and transporters that are involved in
glutamine metabolism. We focused our western blotting
analysis on enzymes that act on glutamine to produce glu-
tamic acid (Fig. 5A, B) and acquired the corresponding
commercially available antibodies.
We were able to detect the glutaminase isoforms, KGA and
GAC, as well as the enzymes PPAT and GFPT1 (see Fig. 5C
for their reaction mechanisms), for which commercially
available antibodies proved functional in our studies. PPAT is
the enzyme committing glutamine-derived nitrogen to de
novo purine synthesis andGFPT1 is the first aswell as the rate-
limiting enzyme in the hexosamine pathway. We generated
human primary CD4+ T cell samples that were at least 70%
infected with HIV-1 NL4.3 as determined by flow cytometry
of intracellular p24Gag (not shown) and the corresponding
uninfected samples that were inoculated with HIV-1 DEnv.
After 48 h of infection, live cells in the culture were
counted and samples corresponding to equal live cell counts
for HIV-1-infected and uninfected conditions were analyzed
by SDS-PAGE and western blotting. After further normali-
zation to the quantity of HSP90 protein in each sample, it
emerged that the glutaminase isoform GAC was consistently
downregulated in the HIV-infected samples compared with
uninfected cells (Fig. 5A), and this was statistically signifi-
cant over multiple quantified experiments (Fig. 5B). Fur-
thermore, an immunoreactive band of lower molecular
weight was consistently observed in the HIV-1-infected
FIG. 4. Metabolic tracing of the fate
of U-13C-labeled glutamine in the su-
pernatant of HIV-1-infected and un-
infected activated primary human
CD4+ T cells by NMR. (A) Time
course NMR analyses of the superna-
tant of HIV-1-infected (HIV-1 NL4.3)
and uninfected (DEnv) cultures at 1 h
(black), 2 h (blue), 3 h (red), and 24 h
(gray) postinfection. Peaks corre-
sponding to the carbons 3 and 4 of
glutamic acid as well as carbon 3 of
lactic acid are indicated above the
spectra. The cluster of peaks at *34
and 29 ppm on the X-axis correspond
the carbons 3 and 4 of the U-13C-
labeled glutamine that was provided to
the cultures. (B) Quantification of the
glutamine, glutamic acid, and lactic
acid abundance in the culture super-
natant at 24 h postinfection as deter-
mined by NMR analysis of five
different donors. Statistical signifi-
cance is indicated by an asterisk
with *p £ .05. NMR, nuclear magnetic
resonance.
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samples, which may correspond to a degradation product or
modified form of GAC (Fig. 5A).
Furthermore,we consistently observed increased expression
of the glutaminase isoform KGA as well as the enzyme PPAT
in the HIV-1-infected compared with uninfected samples, al-
though this only reached statistical significance with the
quantified data for PPAT (Fig. 5A, B). Expression levels of
GFPT1 were unaffected by the HIV-1 infection. We also
confirmed that the liver-specific isoformofglutaminase,GLS2,
is not expressed in HIV-1-infected and uninfected T cells (not
shown). While it is not possible to draw conclusions as to the
overall effect of HIV-1 infection on the cellular glutamine
metabolism from the expression levels of these enzymes alone,
our results do demonstrate that there are considerable changes
in the expression of several enzymes acting on glutamine upon
infection of primary human CD4+ T cells with HIV-1.
Discussion
In this study, we have investigated the effect of HIV-1
infection on the glutamine metabolism of primary human
CD4+ T cells. We report four key observations: (1) HIV-1-
infected primary CD4+ T cells contain higher glutamine
concentrations than uninfected cells; (2) entry of glutamine
into the citric acid cycle is unaffected by HIV-1 infection of
primary CD4+ T cells; (3) the secretion of glutamic acid is
increased upon infection with HIV-1; and (4) the expression
of several enzymes that act on glutamine is responsive to
HIV-1 infection. These changes in the glutamine metabolism
may either serve to support the HIV-1 infection cycle or
represent a cellular response to the infection; we have been
unable to unequivocally assign this distinction. Nonetheless,
these changes in glutamine metabolism are clearly hallmarks
of HIV-1 infection in primary human CD4+ T cells.
Indeed, a recent study of the serum metabolome of HIV-1-
infected individuals showed that glutamine as well as glucose
concentrations were inversely correlated with CD4+ T cell
count, suggesting a physiological link between glutamine and
glucose metabolism with HIV disease progression.29 In-
triguingly, the same was not observed in a cohort of young
(below 18 years of age) HIV-infected individuals, who
maintained similar serum concentrations of glutamine and
glutamate as healthy individuals.30 The reasons for this dif-
ference currently remain unclear.
As regards the increased concentration of glutamine in
HIV-1-infected primary cells (Fig. 2), we consider it most
likely that this is due to increased glutamine uptake by the
cells. Indeed, we did attempt to address this by classical
glutamine uptake assays using radio-labeled glutamine, but
these experiments lacked the sensitivity to discern a quanti-
fiable difference in glutamine uptake by HIV-1-infected and
uninfected cells (not shown). However, the metabolic tracer
experiments monitoring the intracellular fate of 13C-labeled
glutamine provide indirect evidence that the increase in in-
tracellular glutamine is likely to be due to increased uptake.
As the intracellular glutamine pool maintained a 50% ratio of
13C to 12C that was provided in the culture media, there was
clearly no significant intracellular synthesis of glutamine.
FIG. 5. The expression of glutamine-metabolizing enzymes in HIV-infected and uninfected activated primary human
CD4+ T cells as determined by western blotting. (A) Representative western blots showing the expression of HSP90
(loading control), KGA, CAG (both glutaminase isoforms), PPAT, GFPT1, and p24Gag in uninfected (DEnv) and infected
(NL4.3) cells at 48 h postinfection. (B) Quantified data from (A), relative to HSP90 expression and normalized to the
uninfected DEnv control samples. (C) Reactions catalyzed by the KGA, CAG, PPAT, and GFPT1 enzymes. Statistical
significance is indicated by asterisks with **p £ .01.
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Increased intracellular synthesis of glutamine would have
been evident as a reduction in the proportion of cytoplasmic
13C-containing glutamine. Conversely, import of glutamine
would maintain the 1:1 ratio of 13C to 12C, as we did indeed
observe (Fig. 3A).
Glutamine transport can be mediated by a variety of pro-
teins from the solute carrier-type transporter superfamily
with directionality that can be either influx, efflux, or
both.31,32 Glutamine transport into T cells remains incom-
pletely understood as regards transporter identity, substrate
specificity, and directionality.33
It has long been appreciated that glutamine is required to
support T cell activation, including the expression of CD45,
CD71, and IFNc.34 In addition, CD98 consists of SLC7A5
and SLC3A2 subunits that export glutamine in exchange for
importing leucine (and other branched amino acids) to drive
mammalian target of rapamycin (mTOR) activation35 and its
role in T cell activation is well documented.36–38 More re-
cently, it was shown that T cell activation leads to the in-
creased expression of several potential glutamine
transporters and other metabolite transporters39 in a Myc-
regulated manner.40,41
The glutamine transporter SLC1A5 (ASCT2) has been
shown to support murine effector CD4+ T cell differentiation
and is necessary for early phase glutamine uptake after TCR
stimulation and costimulation.42 However, after prolonged
activation, glutamine uptake into murine SLC1A5-/- CD4+ T
lymphocytes was apparent, indicating that other glutamine
transporter must be active in CD4+ T cells.
In the context of HIV-1 infection, the transporter SLC38A1
(or SNAT1) that was originally annotated as a neuronal glu-
tamine transporter43 was recently shown to be downregulated
by the HIV-1 Vpu protein and was shown to mediate alanine,
but not glutamine, uptake into T cells.44 Therefore, there re-
main many open questions as regards the identity as well as
activity of glutamine transporters33,45 and their regulation
during T cell activation and HIV-1 infection.
Our current observation that entry of glutamine-derived
carbon into the citric acid cycle is unaffected by infection of
primary CD4+ T cells with HIV-1 is in line with our previous
study.11 We previously reported that HIV-1-infected primary
CD4+ T cells show increased glycolysis and lactic acid pro-
duction compared with uninfected cells, but mitochondrial
oxygen consumption remained unaffected.11 In that same
study, we also reported that, unlike primary CD4+ T cells, the
T cell lines, CEM-ss and Jurkat, have reduced oxygen con-
sumption rates upon infection with HIV-1. Our current exper-
iments showing reduced entry of glutamine-derived carbon into
the citric acid cycle corroborate those findings, as evidenced by
lower 13C percentages present in glutamic acid, aspartic acid,
and citric acid for CEM-ss and Jurkat cells (Fig. 3).
Investigation of the exometabolome of HIV-1-infected and
uninfected primary CD4+ T cell cultures (Fig. 4) revealed a
faster and greater secretion of glutamine-derived glutamic
acid by HIV-1-infected cells. As the majority of intracellular
glutamic acid (at least 90%, see Fig. 3A, B) is derived from
glutamine, this implies a greater net efflux of glutamic acid
from HIV-1-infected primary CD4+ T cells. The concomitant
reduction in the proportion of glutamine-derived lactic acid
(Fig. 4B) may be explained by the greater glucose-derived
lactic acid production that we and others have previously
reported.10,11
While increased secretion of glutamic acid from HIV-1-
infected T cells has to our knowledge not previously been
reported, there are consistent reports of glutaminase-
dependent glutamic acid secretion from HIV-1-infected
macrophages and microglial cells and this is thought to
contribute to the pathology of AIDS-related dementia.46–53
Our current work suggests that secretion of glutamic acid is
a more general feature of HIV-1-infected cells, although the
underlying mechanisms may be different for each cell-type.
One recent study proposed that the enhanced glutamic acid
production in macrophages is due to HIV-1 Vpr-mediated
enhancement of flux through the glycolytic and citric acid
cycle pathways with a concomitant increase in extracellular
glutamic acid concentrations.54 However, it must be noted that
the majority of that work was carried out with cells transduced
with HIV-1 Vpr instead of HIV-1-infected cells. Datta et al.
therefore attributed an important role to Vpr in modulating
carbon metabolism in macrophages.54 We have not observed
any effect of deleting Vpr from HIV-1 NL4.3 on glycolytic
metabolism in infected CD4+ T cells (not shown: Kavanagh
Williamson et al., article in preparation).
The conversion of glutamine to glutamic acid can be en-
zymatically performed in a variety of ways. The enzyme
glutaminase, of which T cells express the KGA and GAC
isoforms,55 catalyses this step by generating a free NH3
molecule (Fig. 5C). Alternatively, the enzyme PPAT gener-
ates glutamic acid from glutamine as the nitrogen is donated
toward nucleotide biosynthesis and GFPT1 targets the nitro-
gen toward glucosamine biosynthesis (Fig. 5C). There are
many more enzymes that act on glutamine, but antibodies are
not commercially available for all of these. We, therefore,
analyzed the expression of a defined set of enzymes that act on
glutamine and demonstrated differential expression of KGA,
GAC, and PPAT, but not GFPT1, in HIV-1-infected cells.
We note that, while we observed increased expression of
KGA and decreased expression of GAC in HIV-1-infected
CD4+ T cells, the opposite has been reported in infected
macrophages.48,50 The reasons for this difference are as yet
unclear.
In conclusion, our current study demonstrates that cellular
glutamine metabolism is altered upon infection of human
primary CD4+ T cells with HIV-1 and resulting in increased
secretion of glutamic acid from the infected cells. Further-
more, we demonstrated that HIV-1 replication is responsive
to the availability of glutamine, although we were unable to
dissect this from the requirement of glutamine for cell sur-
vival. In conjunction with previous studies on HIV-1-infected
macrophages, our work suggests that glutamic acid secretion
is a more general feature of HIV-1-infected cells. With the
current surge in interest in metabolism in human health and
disease, glutamine metabolism merits further attention as
regards its role in HIV-1 pathogenesis and as a potential
target for future antiretroviral strategies.
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